• Sign up to our Free Newsletter
  • Contact Us
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login/ Register
    • About
  • Issue Archive
  • Advertise

Month: January 2021

Editor's Choice

Why microbiota samples should be collected in all clinical trials?

January 26, 2021 Isabelle de Cremoux

In recent years, the understanding of how the microbiome and human health are linked has expanded considerably. We believe the rise in this understanding and the growing interest towards our microbiome research-focused Health for Life […]

Editor's Choice

Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19

January 20, 2021 Microbiome Times

Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced positive interim results from the K031 non-IND controlled clinical study evaluating outpatients with mild to moderate COVID-19 disease. Patients in this non-IND clinical study were randomized within 48 […]

Pharma & Human Health

Felix Biotechnology announces initiation of a Phase 1/2 study at Yale for targeted phage therapy in the treatment of P. aeruginosa infections

January 20, 2021 Microbiome Times

Felix Biotechnology announced the initiation of CYPHY, a Phase 1/2 investigator-initiated single center trial at Yale University for targeted phage therapy YPT-01 in the treatment of chronic P. aeruginosa infections in cystic fibrosis. This double-blind, […]

Editor's Choice

Poor gut health connected to severe COVID-19, new review shows

January 18, 2021 Microbiome Times

People infected with COVID-19 experience a wide range of symptoms and severities, the most commonly reported including high fevers and respiratory problems. However, autopsy and other studies have also revealed that the infection can affect […]

Finance

Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.

January 13, 2021 Microbiome Times

Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 […]

Pharma & Human Health

Landmark human study is first to reveal strong links between specific gut microbes, diet and health, including weight

January 12, 2021 Microbiome Times

Diets rich in certain plant-based foods are linked with the presence of gut microbes that are associated with a lower risk of developing conditions such as obesity, type 2 diabetes and cardiovascular disease, according to […]

Finance

Eligo inks deal with GSK potentially worth up to $224M

January 12, 2021 Microbiome Times

Eligo Bioscience SA (Eligo) today announced that it has entered into a research and option agreement with GlaxoSmithKline (NYSE: GSK) aimed at advancing Eligobiotics® for the treatment or prevention of acne vulgaris with a pioneering […]

Pharma & Human Health

The incredible, variable bacteria living in your mouth

January 8, 2021 Microbiome Times

Bacteria often show very strong biogeography – some bacteria are abundant in specific locations while absent from others – leading to major questions when applying microbiology to therapeutics or probiotics: how did the bacteria get […]

Animal Health

Nanoplastics alter intestinal microbiome and threaten human health

January 5, 2021 Microbiome Times

We live in a world invaded by plastic. Its role as a chemically stable, versatile and multi-purpose fostered its massive use, which has finally translated into our current situation of planetary pollution. Moreover, when plastic […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview
    June 27, 2022
  • Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers
    April 15, 2022
  • Did you miss Probiota Copenhagen 2022? Catch up now!
    April 12, 2022
  • A new strategy for editing DNA within microbial communities using CRISPR-Cas9 technology
    February 18, 2022
  • Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132
    February 17, 2022
sign up

Sign up to the Microbiome Times newsletterÂ